Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock
Healthcare · Biotechnology · US
$0.15
-22.15%
Last updated Jun 19, 2026 00:00 UTC
LIMN Key Statistics
Market Cap$4.07M
P/E (TTM)-0.05
P/S (TTM)—
P/B (TTM)-0.37
Revenue (TTM)$0.00
EPS (TTM)$-2.91
Dividend Yield—
ROE (TTM)194.96%
Net Margin0.00%
Gross Margin0.00%
52W High$0.36
52W Low$0.13
Analyst View—
Price Target—
Employees3
Volume7,005,408
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
CEO: Chris Kim. Company website
See LIMN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open LIMN in Terminal See plans